MAPT and Alzheimer disease: On the other hand, the current results indicate that DMO could be another alternative energy substrate to the brain and a potential neuroprotective compound in the context of decreased cerebral glucose metabolism in AD; however, the effects of DRB18 in altering other features of AD such as amyloid beta accumulation or increased tau phosphorylation and the possible reversal of such effects by DMO are to be examined thoroughly.